bioAffinity regains Nasdaq compliance; hearing cancelled, listing continues

bioAffinity Technologies, Inc.

Regained compliance with Nasdaq Minimum Bid Price Rule 5550(a)(2) and Rights/Warrants Rule 5560(a) as of Sept 8, 2026.
Previously scheduled Nasdaq Hearings Panel hearing cancelled; BIAF and BIAFW continue trading on Nasdaq Capital Market.
As of Sept 8, 2026: 1,166,625 shares outstanding; aggregate market value ~$10.4M based on closing price.
Staff Determination on July 30, 2026 cited bid price below $1.00 for 30 consecutive days; appeal filed Aug 6, 2026.
CEO Maria Zannes: pleased to regain compliance, focus on CyPath Lung test and pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.